Drugs / VCH 916
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00623649 | Nov 2007 → Oct 2008 | hepatitis C virus infection | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCH 916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00623649 ↗ |
| Route | Oral | “orally administered VCH-916” NCT00623649 ↗ |